CN109609649A - A kind of lncRNA for rectal adenocarcinoma diagnosis and treatment - Google Patents
A kind of lncRNA for rectal adenocarcinoma diagnosis and treatment Download PDFInfo
- Publication number
- CN109609649A CN109609649A CN201910097673.6A CN201910097673A CN109609649A CN 109609649 A CN109609649 A CN 109609649A CN 201910097673 A CN201910097673 A CN 201910097673A CN 109609649 A CN109609649 A CN 109609649A
- Authority
- CN
- China
- Prior art keywords
- gene
- expression
- reagent
- rectal adenocarcinoma
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
It is LOC105376270 the invention discloses a kind of lncRNA for rectal adenocarcinoma diagnosis and treatment, the lncRNA, the invention discloses LOC105376270 to prepare application and corresponding product in rectal adenocarcinoma diagnosing and treating product.The application that the present invention discloses LOC105376270 in the drug candidate of screening treatment rectal adenocarcinoma and in the computation model of building prediction rectal adenocarcinoma.
Description
Technical field
The invention belongs to biomedicine fields, are related to a kind of lncRNA for rectal adenocarcinoma diagnosis and treatment, are specifically related to
lncRNA LOC105376270。
Background technique
Colorectal cancer is a kind of common digestive system tumor, and the disease incidence in China is generally in rise year by year trend
(Xu J,Qin X,Wang J,et al.Chinese guidelines for the diagnosis and
Comprehensive of hepatic metastasis of colorectal cancer [moon .1Cancer Res Clin
Oncol2011,137(9):1379-96.).Rectal adenocarcinoma belongs to one kind of the carcinoma of the rectum, accounts for the 75%~85% of colorectal cancer, is
The common malignant tumour of alimentary canal.In recent years, although Clinics and chemotherapeutics are constantly updated, Colon and rectum is greatly improved
The therapeutic effect of patient, but due to having occurred and that transfer, the prognosis of colorectal cancer patients still do not have when Most patients discovery
Significantly improve (Anaya DA, Becker NS, Abraham NS.Global graying, colorectal cancer and
liver metastasis:new implications for surgical management[1].Crit Rev Oncol
Hematol 2011,77(2):100-8.).Therefore, the research of rectum metastasis of cancer related mechanism is actively developed, new molecule mark is found
Will object and therapy target simultaneously carry out early intervention and individualized treatment, and improving survival has important clinical value and society
It can meaning.
Long-chain non-coding RNA (long noncoding RNA, 1ncRNA) is that a kind of length is greater than the open reading of 200nt shortage
The non-coding RNA of code frame, is mainly realized from epigenetics, transcriptional control and post-transcriptional control etc. to gene expression
Regulation.LncRNA is expressed in the moment of biological growth and development, has tissue and temporal.Research table in recent years
Bright, lncRNA takes part in a variety of vital movements such as genomic imprinting, x chromosome inactivation, chromosome modification and telomere biology
Process.LncRNA can also participate in including swollen in the expression of transcriptional level, post-transcriptional level and epigenetic Level tune gene
The occurrence and development of a variety of diseases of the mankind including tumor.Although related compared to miRNA (microRNA, miRNA)
The document of 1ncRNA and relation between tumor is obviously less, and research is not deep enough, but has been able to determine that lncRNA wide participation is swollen
The occurrence and development process of tumor, and also there is extremely important effect (.Zheng HT, Shi to the diagnosis, treatment and prognosis of tumour
DB,Wang YW,et al.High expression of 1ncRNA MALAT1 suggests a biomarker of
poor prognosis in colorectal cancer[J].Int J Clin Exp Pathol,2014；7(6):3174-
3181.).Therefore, mechanism of action of the lncRNA in tumor development is furtherd elucidate, it will help find new tumour point
The marker of son diagnosis, gene therapy and Index for diagnosis.
Summary of the invention
In order to make up for the deficiencies of the prior art, the purpose of the present invention is to provide a kind of lncRNAs relevant to rectal adenocarcinoma
Marker applies it in clinic, to realize the early diagnosis and therapy of rectal adenocarcinoma, carries out effective prevention, improves and suffer from
The survival rate and life quality of person.
To achieve the goals above, the present invention adopts the following technical scheme:
The present invention provides the applications of LOC105376270, are used to prepare the product of Diagnosis of Rectal gland cancer.
Further, the product includes the reagent for detecting LOC105376270 expression in sample.
Further, the reagent includes by reverse transcription PCR, real-time quantitative PCR, in situ hybridization, chip technology detection
The reagent of LOC105376270 expression.
The present invention provides a kind of products of Diagnosis of Rectal gland cancer, including chip or kit, wherein the chip or examination
Agent box includes the reagent for detecting LOC105376270 expression.
Further, the reagent for LOC105376270 expression being detected in the chip includes specific recognition
The probe of LOC105376270 gene；The reagent that LOC105376270 expression is detected in the kit includes that specificity expands
Increase the primer of LOC105376270 gene or the probe of specific recognition LOC105376270 gene.
Further, the primer sequence of specific amplification LOC105376270 gene is as shown in NO.1~2 SEQ ID.
In the present invention, kit further include container, operation instructions, positive control, negative control object, buffer,
Auxiliary agent or solvent, and the operation instructions with kit are described and how to be detected using kit, and how
Tumor development is judged using testing result, therapeutic scheme is selected.
The component of kit can pack in the form of aqueous medium or in the form of freeze-drying.Container appropriate in kit
It include typically at least a kind of bottle, test tube, flask, PET bottle, syringe or other containers, wherein a kind of component can be placed, and
And preferably, suitably equal part can be carried out.There are more than one group timesharing in kit, generally also will include in kit
Second, third or other additional containers, wherein being positioned separately additional component.However, the component of various combination can be wrapped
It is contained in a bottle.Kit of the invention will include generally also a kind of container for being used to accommodate reactant, seal to be used for
Commercial distribution.This container may include the plastic containers of injection molding or blowing mould, wherein can retain required bottle.
In the present invention, chip further includes solid phase carrier, and the solid phase carrier includes plastic products, microparticle, membrane carrier
Deng.The plastic products can be combined by non-covalent or physical absorption mechanism with antibody or proteantigen, most common plastics
Product is small test tube, globule and micro-reaction plate made of polystyrene；The microparticle is aggregated by high polymer monomer
Microballoon or particle, diameter are mostly micron, due to can with the functional group in conjunction with protein, easily with antibody (antigen) formationization
Coupling is learned, binding capacity is big；The membrane carrier includes the miillpore filters such as nitrocellulose filter, glass fibre element film and nylon membrane.
The present invention provides the applications of LOC105376270 a kind of, for constructing the computation model of prediction rectal adenocarcinoma.
As those of skill in the art know, can be implemented in various ways and realize by marker levels and certain may
The step of property or risk association get up.Preferably, the mathematically measurement of composite marker object and one or more other markers
Concentration, and combined value is associated with basic diagnosis problem.It can be incited somebody to action by any suitable prior art mathematical method
The measurement of marker levels is combined.
Preferably, the mathematical algorithm applied in marker combination is a kind of logarithmic function.Preferably, using such mathematics
Algorithm or such logarithmic function the result is that single value.According to basic diagnosis problem, can easily by such value with it is for example a
Body associates about the risk of rectal adenocarcinoma or with the other intentional diagnostic uses for helping to assess rectal adenocarcinoma patient.With one
Kind preferred mode, such logarithmic function obtain as follows: individual segregation a) being entered group, such as normal person, has rectal adenocarcinoma
The individual of risk, the patient with rectal adenocarcinoma etc., b) significant difference between these groups is identified by univariate analysis
Marker, c) logarithmic regressions analysis to be to assess the independent difference values that can be used for assessing these difference groups of marker, and d) structure
It builds logarithmic function and carrys out composition independency difference value.In such analysis, marker is no longer independent, but represents one
Marker combination.
Logarithmic function for marker combination to be got up with disease association is preferably developed using by applied statistical method
With the algorithm of acquisition.For example, suitable statistical method is discriminant analysis (DA) (i.e. linear, secondary, regular DA), Kernel method
(i.e. SVM), nonparametric technique (i.e. k- nearest neighbor classifiers), PLS (partial least square), method (the i.e. logic based on tree
Recurrence, CART, random forest method, boosting/bagging method), generalized linear model (i.e. logarithm regression), the side based on principal component
Method (i.e. SIMCA), broad sense Additive Model, the method based on fuzzy logic, the method based on artificial neural network and genetic algorithms.Skillfully
Technical staff merges in the suitable statistical method of selection to assess marker group of the invention thus to obtain suitable mathematical algorithm
Aspect will not be problematic.In one embodiment, for obtaining the statistics side of mathematical algorithm used in assessment rectal adenocarcinoma
Method is selected from DA (i.e. linear, secondary, rule based judgment analysis), Kernel method (i.e. SVM), nonparametric technique (i.e. k- nearest-neighbors
Classifier), PLS (partial least square), method (i.e. logistic regression, CART, random forest method, boosting side based on tree
Method) or generalized linear model (i.e. logarithm regression).
The present invention provides the applications of LOC105376270 a kind of, for screening the drug candidate for the treatment of rectal adenocarcinoma.
Further, screening step is as follows:
The system expressed or containing LOC105376270 gene is handled with substance to be screened；With
Detect the expression of LOC105376270 gene in the system；
Wherein, if the substance to be screened can inhibit the level of LOC105376270 gene, show that this is to be screened
Substance is the drug candidate for treating rectal adenocarcinoma.
The system is selected from: cell system, subcellular system, solution system, organizational framework, organ systems or animal body
System.
The candidate substances include but is not limited to: for LOC105376270 gene or its upstream or downstream gene design
Disturbing molecule, nucleic acid inhibitor, small molecule compound etc..
The present invention provides the applications of LOC105376270 a kind of, are used to prepare the pharmaceutical composition for the treatment of rectal adenocarcinoma.
Further, described pharmaceutical composition includes the inhibitor of LOC105376270.The inhibitor is selected from: with
LOC105376270 or its transcript are target sequence and the interference for being able to suppress LOC105376270 gene expression or genetic transcription
Molecule, comprising: shRNA (children purpura nephritis), siRNA (siRNA), dsRNA, Microrna, antisense nucleic acid, or can express or
Form the construction of the shRNA, siRNA, dsRNA, Microrna, antisense nucleic acid.
Further, the inhibitor is siRNA.As used herein, " siRNA " refers to that a kind of short-movie section is double
Chain RNA molecule, can be using the mRNA of homologous complementary sequence as the target specific mRNA of degradation, this process is exactly RNA interference
(RNA interference) process.SiRNA can be prepared into the form of double-strandednucleic acid, it contains a positive-sense strand and one
A antisense strand, this two chains only form double-strand under conditions of hybridization.One double-stranded RNA compound can be by being separated from each other just
It is prepared by adopted chain and antisense strand.Therefore, for example, complementary positive-sense strand and antisense strand are chemical synthesis, and can be passed through thereafter
Anneal generates the double-stranded RNA compound of synthesis.
As a kind of optional way of the invention, the inhibitor of the LOC105376270 is also possible to a kind of " small hair
Press from both sides RNA (Small hairpin RNA, shRNA) ", it is the non-coding small RNA molecular for being capable of forming hairpin structure, bobby pin
RNA can be by RNA interference channel come the expression of suppressor.As above-mentioned, shRNA can be expressed by double-stranded DNA template.It is double
Chain DNA template is inserted into a carrier, such as plasmid or viral vectors, be then connected in vitro or in vivo a promoter into
Row expression.ShRNA under the action of DICER enzyme, can be cut into siRNA molecule, hence into RNAi in eukaryocyte
Approach." shRNA expression vector " refers to plasmid of some this fields conventionally used for constructing shRNA structure, deposits on the usual plasmid
At " intervening sequence " and positioned at the multiple cloning sites on " intervening sequence " both sides or for replacing sequence, so that people can incite somebody to action
ShRNA (or the like) corresponding DNA sequence dna is inserted into the confession of multiple cloning sites or replacement thereon by way of forward and reverse
Sequence is replaced, the RNA after DNA sequence dna transcription can form shRNA (Short Hairpin) structure." the shRNA expression
Carrier " can be bought by commercially available approach completely obtain at present, such as some viral vectors.
Further, described pharmaceutical composition further includes pharmaceutically acceptable carrier, and pharmaceutically acceptable carrier includes
(but being not limited to) diluent, adhesive, surfactant, Humectant, absorption carrier, lubricant, filler, disintegrating agent.
Pharmaceutical composition of the invention can also be with the drug combination of other treatment rectal adenocarcinoma, and other therapeutic compound can
To be administered simultaneously with main active constituent, or even it is administered simultaneously in same composition.
In the present invention, " marker ", " biomarker " " gene marker " can be general, and referring to has specificity raw
The molecular indicator of object characteristic, biochemical characteristics or aspect, can be used for determining presence or absence of specified disease or
The severity of situation and/or specified disease or situation.
In the present invention, the gene for transcribing LOC105376270 is to be located at people No. 9 long-armed 3rd area 3 of dye to take, in the present invention
LOC105376270 includes wild type, saltant type or its segment.Currently, the LOC105376270 disclosed in genebank exists
3 kinds of transcription products, sequence is respectively as shown in XR_930342.1, XR_930341.1 and XR_930343.2.It is familiar with the skill of this field
Art personnel will be seen that, when carrying out bioinformatic analysis to sequencing result, it will usually by sequencing result and known genome
It is compared, as long as sequencing fragment can compare on relevant gene, so that it may regard the expression of the gene as, therefore,
The different transcription products of LOC105376270 are also contained in the present invention.
The present invention can use the expression of any method known in the art measurement gene.Those skilled in the art
It should be appreciated that the means of measurement gene expression are not importances of the invention.Biological marker can be detected on transcriptional level
The expression of object.
Some detections of lncRNA level or quantitative approach are known in the art and are suitable for provided herein
Method is to measure the level of biomarker.Illustrative method includes but is not limited to RNA trace (northern blots), core
The method of ribonuclease T. protection test and based on PCR.When biomarker is lncRNA molecule, lncRNA sequence or its segment
It can be used for preparing the probe of at least partial complementarity.Then using the method for such as based on PCR, RNA blotting (Northern
Blotting) or test strips detect any suitable measuring methods such as (dipstick assay), can be in probe in detecting sample
LncRNA sequence.
The measuring method can change according to the type of required lncRNA information.Illustrative method includes but unlimited
In the method (for example, qRT-PCR) of RNA trace (Northern blots) and based on PCR.The methods of qRT-PCR can also be right
The amount of lncRNA carries out accurate quantitative analysis in sample.
In a specific embodiment of the present invention, experiment be all to be completed according to being at least repeated 3 times, result data be all with
The mode of mean+SD indicates, using SPSS18.0 statistical software come for statistical analysis, difference between the two
It is different to be examined using t, it is believed that there is statistical significance as P < 0.05.
Advantages of the present invention with the utility model has the advantages that
Present invention firstly discovers that the differential expression of LOC105376270 is related to the occurrence and development of rectal adenocarcinoma, pass through inspection
The expression for surveying LOC105376270 may determine that whether subject suffers from rectal adenocarcinoma.
The invention discloses a kind of methods of the drug candidate of screening treatment rectal adenocarcinoma, by whether detecting substance to be selected
The expression of LOC105376270 can be lowered to judge whether substance to be screened is the drug candidate for treating rectal adenocarcinoma.
Detailed description of the invention
Fig. 1 is the expression figure using QPCR detection LOC105376270 gene in rectal adenocarcinoma tissue.
Specific embodiment
Below with reference to specific embodiment further illustrate the present invention, the embodiment of the present invention for explaining only the invention,
It is not intended to limit protection scope of the present invention.
Experimental method used in following embodiments is conventional method unless otherwise specified.
The materials, reagents and the like used in the following examples is commercially available unless otherwise specified.
Embodiment 1 screens gene marker relevant to rectal adenocarcinoma
1, sample collection
It collects 5 rectal adenocarcinoma tissue samples and corresponding cancer beside organism's sample, all cases is equal before surgery
Chemotherapy and radiation is not received, excludes other tumor diseases, autoimmune disease and serious chronic disease, and all patients are equal
Informed consent, and pass through the agreement of the committee, organizational ethics.
2, the preparation of RNA sample
The extraction of tissue RNA is carried out using the tissue RNA extracts kit of QIAGEN, concrete operations by specification carries out.
3, total serum IgE is quantitative and purity analysis
The RNA of said extracted is subjected to agarose gel electrophoresis, using Nanodrop2000 to the concentration of mentioned RNA and pure
Degree is detected, and agarose gel electrophoresis detects RNA integrality, and Agilent2100 measures RIN value.Single requirement for construction data base RNA is total
5 μ g are measured, concentration >=200ng/ μ L, OD260/280 is between 1.8~2.2.
4, construction cDNA library
The rRNA in total serum IgE is removed using Ribo-Zero kit；To complete RNA sequence, using metal from
Son is interrupted at random, by RNA random fracture at the small fragment of 200bp or so；Using Illumina TruseqTM RNA
The building of sample Prep Kit progress cDNA library.
5, it is sequenced
Using Illumina X-Ten microarray dataset, 2*150bp sequencing is carried out.
6, high-throughput transcript profile sequencing data analysis
Bioinformatic analysis is carried out to transcript profile sequencing data, reads is trimmed with cutadapt, after Quality Control
Comparing to reference genome GRCh38 on, cuffquant quantify lncRNA expression quantity and normalization output；
Cuffdiff compares control group with the differential expression of disease group lncRNA, the screening criteria of differential expression lncRNA: p_value <
0.05, | log2FC|>1。
7, result
The results show that LOC105376270 is on the expression in rectal adenocarcinoma tissue is significant compared with cancer beside organism
It adjusts.
The differential expression of 2 QPCR sequence verification LOC105376270 gene of embodiment
1, large sample QPCR verifying is carried out to LOC105376270 gene differential expression.It is received according to the sample in embodiment 1
Mode set selects rectal adenocarcinoma cancer beside organism and each 30, rectal adenocarcinoma tissue.
2, RNA is extracted
RNA sample is extracted using the tissue RNA extracts kit of QIAGEN, concrete operations are detailed in specification.
3、QPCR
1) reverse transcription reaction
LncRNA is carried out using FastQ μ ant the first chain of cDNA synthetic agent box (article No.: KR106) of Tiangen company
Reverse transcription, the first reaction of removal genomic DNA, are added 5 × gDNA B μ ffer, 2.0 μ l, 1 μ g of total serum IgE adds in test tube
Rnase Free ddH2O makes total volume to 10 μ l, 42 DEG C of heating 3min in water-bath, then by 10 × Fast RT B μ ffer
2.0 μ l, RT Enzyme Mix, 1.0 μ l, FQ-RT Primer Mix, 2.0 μ l, RNase Free ddH25.0 μ l of O, mixing
After be added in above-mentioned test tube and be mixed together totally 20 μ l, 42 DEG C of heating 15min, 95 DEG C of heating 3min in water-bath.
2) design of primers
QPCR amplimer is designed according to the coded sequence of LOC105376270 gene and GAPDH gene in Genebank,
When carrying out the design of primers of LOC105376270, selects the consensus of different transcription product sequences to be designed, specifically draw
Object sequence is as follows:
LOC105376270 gene:
Forward primer is 5 '-CCACTCTGTTTCTTCTTC-3 ' (SEQ ID NO.1)；
Reverse primer is 5 '-ACACTCACAAATCTCTCT-3 ' (SEQ ID NO.2).
GAPDH gene:
Forward primer is 5 '-AATCCCATCACCATCTTCCAG-3 ' (SEQ ID NO.3)；
Reverse primer is 5 '-GAGCCCCAGCCTTCTCCAT-3 ' (SEQ ID NO.4).
3) QPCR amplification is examined
It with SuperReal PreMix Plus (SYBR Green) (article No.: FP205), is expanded, experimental implementation is by production
Product specification carries out.
Using 20 μ l reaction systems: 2 × SuperReal PreMix Plus 10 μ l, each 0.6 μ of forward and reverse primer (10 μM)
L, 5 × ROX Reference Dye△2 μ l, 2 μ l of DNA profiling, 4.8 μ l of sterile purified water.3 parallel pipes are arranged in each sample,
All amplified reactions are repeated three times the above reliability to guarantee result.
Amplification program are as follows: 95 ° of 15min, (95 DEG C of 10s, 55 DEG C of 30s, 72 DEG C of 32s) × 40 circulations.
4) screening of cDNA template concentrations
After each sample cDNA is mixed, 10 times of gradient dilutions are carried out as template, sample respectively takes 2 μ l to make mould after dilution
Plate is expanded with target gene primer and reference gene primer respectively, while in 60-95 DEG C of progress melt curve analysis analysis, root
The screening of template concentrations is carried out according to amplification efficiency height and the unimodal principle of solubility curve.
According to solubility curve, it can be seen that when 10 times of dilutions of carry out of cDNA, the amplification efficiency of PCR is higher, and dissolution is bent
Line is unimodal relatively good.
5) sample RealTime PCR is detected
2 μ l will be taken to make template after 10 times of each sample cDNA dilutions, respectively with target gene primer and reference gene primer into
Row amplification.Simultaneously in 60-95 DEG C of progresss solubility curve analysis, purpose band is determined by melt curve analysis analysis and electrophoresis, 2-ΔΔCT
Method carries out relative quantification.
4, result
QPCR result is as shown in Figure 1, compared with cancer beside organism, on LOC105376270 is expressed in rectal adenocarcinoma tissue
It adjusts, difference has statistical significance (P < 0.05)；The cancerous tissue sample for wherein expressing up-regulation has 30, prompts LOC105376270
It can be used as the diagnosing and treating that molecular marker is applied to rectal adenocarcinoma.
The explanation of above-described embodiment is only intended to understand method and its core concept of the invention.It should be pointed out that for this
For the those of ordinary skill in field, without departing from the principle of the present invention, several improvement can also be carried out to the present invention
And modification, these improvement and modification will also be fallen into the protection scope of the claims in the present invention.
Sequence table
<110>Taishan Hospital's Hospital Attached to Taishan Medical College
<120>a kind of lncRNA for rectal adenocarcinoma diagnosis and treatment
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 1
ccactctgtt tcttcttc 18
<210> 2
<211> 18
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
acactcacaa atctctct 18
<210> 3
<211> 21
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
aatcccatca ccatcttcca g 21
<210> 4
<211> 19
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 4
gagccccagc cttctccat 19
Claims (10)
1.LOC105376270 application, which is characterized in that be used to prepare the product of Diagnosis of Rectal gland cancer.
2. application according to claim 1, which is characterized in that the product includes LOC105376270 table in detection sample
Up to horizontal reagent.
3. application according to claim 2, which is characterized in that the reagent includes passing through reverse transcription PCR, real-time quantitative
PCR, in situ hybridization, chip technology detection LOC105376270 expression reagent.
4. a kind of product of Diagnosis of Rectal gland cancer, which is characterized in that including chip or kit, wherein the chip or reagent
Box includes the reagent for detecting LOC105376270 expression.
5. product according to claim 4, which is characterized in that detect LOC105376270 expression in the chip
Reagent includes the probe of specific recognition LOC105376270 gene；LOC105376270 expression is detected in the kit
Reagent include the primer of specific amplification LOC105376270 gene or the probe of specific recognition LOC105376270 gene.
6. product according to claim 5, which is characterized in that the primer sequence of specific amplification LOC105376270 gene
As shown in NO.1~2 SEQ ID.
7.LOC105376270 application, which is characterized in that for construct prediction rectal adenocarcinoma computation model.
8.LOC105376270 application, which is characterized in that for screen treatment rectal adenocarcinoma drug candidate.
9.LOC105376270 application, which is characterized in that be used to prepare treatment rectal adenocarcinoma pharmaceutical composition.
10. application according to claim 9, which is characterized in that described pharmaceutical composition includes the suppression of LOC105376270
Preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910097673.6A CN109609649B (en) | 2019-01-31 | 2019-01-31 | lncRNA for diagnosing and treating rectal adenocarcinoma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910097673.6A CN109609649B (en) | 2019-01-31 | 2019-01-31 | lncRNA for diagnosing and treating rectal adenocarcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109609649A true CN109609649A (en) | 2019-04-12 |
| CN109609649B CN109609649B (en) | 2021-09-24 |
Family
ID=66021687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910097673.6A Active CN109609649B (en) | 2019-01-31 | 2019-01-31 | lncRNA for diagnosing and treating rectal adenocarcinoma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109609649B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116162708A (en) * | 2022-12-29 | 2023-05-26 | 上海志药科技有限公司 | Application of lncRNA LOC105376270 in preparation of kit for diagnosing primary liver cancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108998532A (en) * | 2018-08-31 | 2018-12-14 | 北京泱深生物信息技术有限公司 | A kind of diagnosis and treatment marker of rectal adenocarcinoma |
-
2019
- 2019-01-31 CN CN201910097673.6A patent/CN109609649B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108998532A (en) * | 2018-08-31 | 2018-12-14 | 北京泱深生物信息技术有限公司 | A kind of diagnosis and treatment marker of rectal adenocarcinoma |
Non-Patent Citations (1)
| Title |
|---|
| ACCESSION：XR_930343.2: "PREDICTED: Homo sapiens uncharacterized LOC105376270 (LOC105376270), transcript variant X2, ncRNA", 《GENBANK DATABASE》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116162708A (en) * | 2022-12-29 | 2023-05-26 | 上海志药科技有限公司 | Application of lncRNA LOC105376270 in preparation of kit for diagnosing primary liver cancer |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109609649B (en) | 2021-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190241966A1 (en) | Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples | |
| CN102369294B (en) | Non-small cell lung cancer detection marker, detection method thereof, related reagent kit and biochip | |
| Bloomston et al. | MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis | |
| Xu et al. | miR-1 induces growth arrest and apoptosis in malignant mesothelioma | |
| CN101942502A (en) | Pancreatic cancer marker, and detection method, kit and biochip thereof | |
| US20230227914A1 (en) | Biomarkers of oral, pharyngeal and laryngeal cancers | |
| CN101988061A (en) | Breast cancer detecting marker as well as detecting method, kit and biological chip thereof | |
| CN101988059A (en) | Gastric cancer detection marker and detecting method thereof, kit and biochip | |
| CN109609648A (en) | LncRNA marker relevant to liver cancer and its detection primer and application | |
| CN111187840B (en) | Biomarker for early breast cancer diagnosis | |
| CN109468382A (en) | Application of the lncRNA in adenocarcinoma of lung diagnosis and treatment | |
| CN107217105B (en) | Cancer combined diagnosis marker and application thereof | |
| CN109913554A (en) | A kind of lncRNA marker relevant to breast cancer | |
| US20130084241A1 (en) | DEVELOPMENT OF miRNA DIAGNOSTICS TOOLS IN BLADDER CANCER | |
| CN109609649A (en) | A kind of lncRNA for rectal adenocarcinoma diagnosis and treatment | |
| CN110129444A (en) | It is a kind of detect radioactive damage reagent and its application | |
| CN109825595A (en) | LncRNA marker relevant to breast cancer and its detection primer and application | |
| CN107299129A (en) | Circle nucleic acid as breast cancer biomarker application | |
| CN108998532A (en) | A kind of diagnosis and treatment marker of rectal adenocarcinoma | |
| WO2014057279A1 (en) | Micro-rna biomarkers for prostate cancer | |
| CN110592219B (en) | lncRNA diagnosis and treatment marker for breast cancer | |
| CN109628594B (en) | One kind long-chain non-coding RNA relevant to liver cancer and its application | |
| CN108728439A (en) | The finger-print of tiny RNA composition and its application in Diagnosis of Bladder | |
| Yang et al. | Individualized prediction of survival by a 10-long non-coding RNA-based prognostic model for patients with breast cancer | |
| EP3835434A1 (en) | Kit, device and method for detecting prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |